Medical News

WCD Reduces All-Cause Mortality, Not Sudden Cardiac Death, Post MI

Wearable cardioverter-defibrillator (WCD) did not cut down the risk of sudden cardiac death (SCD), but it diminished the risk of all-cause mortality...

20 Mar, 2018

Email this page
Prolonged DAPT Remains the Standard of Care for ACS Patients After PCI

Prolonged (≥12 months) dual antiplatelet therapy (DAPT) without excessive risk of bleeding should remain the standard of care for acute coronary...

16 Mar, 2018

Email this page
Large Day-To-Day Temperature Fluctuations, Hike the Risk of MI

Large changes in temperature on day-to-day basis can potentially hike up the risk of myocardial infarction (MI), suggested a recent study. Drastic...

15 Mar, 2018

Email this page
Switching to Riociguat in PAH and CTEPH Patients, A Feasible Option

Changing over to riociguat therapy in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)...

14 Mar, 2018

Email this page

Key Trials

Prasugrel is Superior or Equivalent to Ticagrelor in ACS Patients undergoing PCI: A Systematic Review and Meta-Analysis

Meta-analysis of 9 trials indicates that prasugrel is equivalent or superior to ticagrelor in ACS patients undergoing PCI.

Efficacy and Safety of Sacubitril/Valsartan in HFrEF Patients with Low SBP: Insights from PARADIGM-HF

The present analysis evaluated the efficacy and safety of sacubitril/over enalapril  in HF patients across different levels of SBP.

Sacubitril/Valsartan in HFrEF Patients: Assessing the Benefits-Harms Balance

The present study is a critical appraisal of the existing evidence on the benefits and harms of sacubitril/valsartan in patients with HFrEF.

Sacubitril/Valsartan Enhances Glycemic Control in Heart Failure Patients with Diabetes

As per the study sacubitril/valsartan causes greater reduction in HbA1c vs. enalapril and cuts new insulin initiation in diabetes patients with...

Slide Library

Chronic Thromboembolic Pulmonary Hypertension

Chronic thromboembolic pulmonary hypertension (CTEPH) is the presence of mean pulmonary artery pressure (mPAP) ≥ 25 mmHg following an episode of...

Email this page
Diabetic Dyslipidemia

Dyslipidemia is one of the key risk factors for cardiovascular disease (CVD) in diabetes mellitus. This slide set provides information on the...

Email this page
Ambrisentan in PAH

Ambrisentan is a propanoic acid, non-sulfonamide, selective endothelin type A (ETA) receptor antagonist which is used in pulmonary arterial...

Email this page
Hypertension: The Indian Perspective

In India, hypertension has reached epidemic proportions and as per the latest estimates, one in 3 adults in India has hypertension. This slide set...

Email this page

Our Publications

Azmarda (Sacubitril/Valsartan) FAQs

This booklet on frequently asked questions on sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) provides...

Retefast (Reteplase) Datasheet

This datasheet provides an overview on the pharmacology, clinical efficacy, safety, indications and dosage of reteplase.

Pulmonary Hypertension – An Update

This article summarises the definition, classification, pathogenesis, assessment, prognosis, diagnosis and treatment for PH.

The Changing Landscape of CV Risk Reduction - Is LDL Lowering Sufficient: Questions & Answers (Dr. Michael Miller, USA)

Here is a set of questions addressed by Dr. Michael Miller, a renowned cardiologist and lipidologist during the “PROMISE” meet held in India.

Patient Education

Understanding Angioplasty

Angioplasty is a life-saving procedure to open up blocked or narrowed blood vessels. This document gives a brief idea about the procedure.

Managing Your Angina

It explains the causes, risk factors, symptoms and treatment options for angina, as well as the various do’s and don’t’s in a patient-friendly...

Understanding Obesity

This document explains what is obesity, what is the impact of obesity on overall health and what are the benefits of weight loss. 


Know more about the risk factors, associated ill-effects and tips for management of hypertension or high blood pressure. 


What percent of your patients who need oral anticoagulation, receive warfarin?
17% (1 vote)
17% (1 vote)
0% (0 votes)
17% (1 vote)
50% (3 votes)
Almost all
0% (0 votes)
Total votes: 6